AR112602A1 - ANTICUERPOS ANTI-TrkB - Google Patents
ANTICUERPOS ANTI-TrkBInfo
- Publication number
- AR112602A1 AR112602A1 ARP180101558A AR112602A1 AR 112602 A1 AR112602 A1 AR 112602A1 AR P180101558 A ARP180101558 A AR P180101558A AR 112602 A1 AR112602 A1 AR 112602A1
- Authority
- AR
- Argentina
- Prior art keywords
- trkb antibodies
- trkb
- antibodies
- diagnostic
- vector
- Prior art date
Links
- 239000000556 agonist Substances 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Anticuerpos agonistas anti-TrkB y métodos terapéuticos y de diagnóstico y composiciones para su uso. Vector y célula huésped.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17175122 | 2017-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR112602A1 true AR112602A1 (es) | 2019-11-20 |
Family
ID=59034551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180101558 AR112602A1 (es) | 2017-06-09 | 2018-06-08 | ANTICUERPOS ANTI-TrkB |
Country Status (22)
Country | Link |
---|---|
US (3) | US10793634B2 (es) |
EP (1) | EP3635004A1 (es) |
JP (2) | JP7267208B2 (es) |
KR (1) | KR20200017421A (es) |
CN (1) | CN110719916B (es) |
AR (1) | AR112602A1 (es) |
AU (1) | AU2018279184B2 (es) |
BR (1) | BR112019023742A2 (es) |
CA (1) | CA3063965A1 (es) |
CL (1) | CL2019003557A1 (es) |
CO (1) | CO2019013718A2 (es) |
EA (1) | EA201992883A1 (es) |
IL (1) | IL271067B2 (es) |
MA (1) | MA49257A (es) |
MX (1) | MX2019014714A (es) |
MY (1) | MY202315A (es) |
PE (1) | PE20200173A1 (es) |
PH (1) | PH12019502694A1 (es) |
SG (1) | SG11201911814UA (es) |
TW (2) | TW202342100A (es) |
UA (1) | UA127967C2 (es) |
WO (1) | WO2018224630A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3630822A1 (en) * | 2017-06-02 | 2020-04-08 | Boehringer Ingelheim International GmbH | Anti-cancer combination therapy |
WO2021094259A1 (en) | 2019-11-11 | 2021-05-20 | Boehringer Ingelheim International Gmbh | Npy2 receptor agonists |
EP4232474A1 (en) | 2020-10-21 | 2023-08-30 | Boehringer Ingelheim International GmbH | Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases |
WO2023125485A1 (en) * | 2021-12-28 | 2023-07-06 | 4B Technologies (Beijing) Co., Limited | TrkB ANTIBODY AND APPLICATION THEREOF |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
EP1891114A2 (en) | 2005-06-06 | 2008-02-27 | Wyeth | Anti-trkb monoclonal antibodies and uses thereof |
WO2008058127A2 (en) * | 2006-11-09 | 2008-05-15 | Irm Llc | Agonist trkb antibodies and uses thereof |
MX2009006794A (es) * | 2006-12-20 | 2009-07-02 | Rinat Neuroscience Corp | Agonistas del receptor tirosina quinasa b para el tratamiento de trastornos autoinmunes. |
CA2701189C (en) * | 2007-10-11 | 2017-05-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists |
CN101909647A (zh) * | 2007-10-23 | 2010-12-08 | 诺瓦提斯公司 | TrkB抗体用于治疗呼吸病症的用途 |
EA028621B1 (ru) | 2008-01-17 | 2017-12-29 | Новартис Аг | АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, КОТОРЫЙ СПЕЦИФИЧНО СВЯЗЫВАЕТ РЕЦЕПТОРНУЮ ТИРОЗИНКИНАЗУ (TrkB), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, И КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ УКАЗАННУЮ КОМПОЗИЦИЮ |
AU2009211340B2 (en) * | 2008-02-04 | 2013-09-12 | Lay Line Genomics S.P.A. | Anti-TrkA antibodies and derivatives thereof |
US8203009B2 (en) * | 2008-07-28 | 2012-06-19 | Emory University | Neurotrophic activity of deoxygedunin |
WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
WO2011103667A1 (en) | 2010-02-26 | 2011-09-01 | 6452728 Canada Inc. | Agonistic antibodies to trkb receptors and uses thereof |
EP2579870B1 (en) * | 2010-06-09 | 2018-02-14 | Emory University | Trkb agonists and methods of use |
US9200080B2 (en) | 2010-09-03 | 2015-12-01 | Horacio Uri Saragovi | Agonistic antibodies to TrkC receptors and uses thereof |
GB2491106A (en) | 2011-05-18 | 2012-11-28 | Univ Basel | Antibodies against tropomyosin-related kinase B receptors |
ES2936810T3 (es) | 2014-05-16 | 2023-03-22 | Pfizer | Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería |
JP7023461B2 (ja) | 2015-07-28 | 2022-02-22 | オトノミ―,インク. | 耳の疾病の処置のためのtrkb又はtrkcアゴニスト組成物及び方法 |
KR20180081522A (ko) | 2015-11-17 | 2018-07-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 신경계 및 다른 장애의 치료를 위한 결합 효능제 |
EA202090966A1 (ru) | 2017-11-30 | 2020-08-26 | Ридженерон Фармасьютикалз, Инк. | МОНОКЛОНАЛЬНЫЕ АНТИ-TrkB АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
-
2018
- 2018-06-07 US US16/002,058 patent/US10793634B2/en active Active
- 2018-06-08 JP JP2019567701A patent/JP7267208B2/ja active Active
- 2018-06-08 TW TW112123529A patent/TW202342100A/zh unknown
- 2018-06-08 TW TW107119755A patent/TWI808086B/zh active
- 2018-06-08 BR BR112019023742A patent/BR112019023742A2/pt unknown
- 2018-06-08 MA MA049257A patent/MA49257A/fr unknown
- 2018-06-08 MY MYPI2019007297A patent/MY202315A/en unknown
- 2018-06-08 MX MX2019014714A patent/MX2019014714A/es unknown
- 2018-06-08 UA UAA201911908A patent/UA127967C2/uk unknown
- 2018-06-08 EP EP18731764.9A patent/EP3635004A1/en active Pending
- 2018-06-08 IL IL271067A patent/IL271067B2/en unknown
- 2018-06-08 AU AU2018279184A patent/AU2018279184B2/en active Active
- 2018-06-08 AR ARP180101558 patent/AR112602A1/es unknown
- 2018-06-08 CN CN201880038098.6A patent/CN110719916B/zh active Active
- 2018-06-08 CA CA3063965A patent/CA3063965A1/en active Pending
- 2018-06-08 KR KR1020197037817A patent/KR20200017421A/ko active Search and Examination
- 2018-06-08 PE PE2019002525A patent/PE20200173A1/es unknown
- 2018-06-08 WO PCT/EP2018/065107 patent/WO2018224630A1/en active Application Filing
- 2018-06-08 EA EA201992883A patent/EA201992883A1/ru unknown
- 2018-06-08 SG SG11201911814UA patent/SG11201911814UA/en unknown
-
2019
- 2019-11-28 PH PH12019502694A patent/PH12019502694A1/en unknown
- 2019-12-05 CL CL2019003557A patent/CL2019003557A1/es unknown
- 2019-12-05 CO CONC2019/0013718A patent/CO2019013718A2/es unknown
-
2020
- 2020-08-26 US US17/002,907 patent/US11866501B2/en active Active
-
2023
- 2023-04-19 JP JP2023068735A patent/JP7505084B2/ja active Active
- 2023-11-28 US US18/520,650 patent/US20240101689A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017000590A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
CR20170230A (es) | Anticuerpos anti-cd79b y métodos de uso | |
CL2020000281A1 (es) | Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39 y métodos de uso de anticuerpos anti-cd39 | |
BR112019012343A2 (pt) | anticorpos il-11ra | |
BR112019012342A2 (pt) | anticorpos il-11 | |
CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
ECSP17016797A (es) | Indazoles sustituidos con benzilo como inhibidores de bub1 | |
CR20180013A (es) | Anticuerpos anti-tau y métodos de uso. | |
CR20160362A (es) | Anticuerpos anti-jagged1 y metodos de uso | |
BR112018074922A2 (pt) | agonista de receptores de glucocorticoides e seus imunoconjugados | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
BR112017008666A2 (pt) | anticorpos anti-fgfr2/3 e métodos de uso dos mesmos | |
CR20160141A (es) | Formulaciones de anticuerpos anti-pdl1 | |
BR112017004141B8 (pt) | Agente de imagemamento e seu uso | |
CR20160314A (es) | Anticuerpos anti-cd3 y metodos de uso | |
CL2016001432A1 (es) | Nuevos anticuerpos anti-dpep3 y métodos de uso | |
DOP2015000219A (es) | Compuestos de heteroarilo y sus usos | |
CR20190271A (es) | Anticuerpos antitau y métodos de uso | |
CR20140212A (es) | Anticuerpos anti-htra1 y métodos de uso | |
CR20150247A (es) | Anticuerpos de antihemaglutinina y métodos de uso | |
CR20140382A (es) | Anticuerpos anti-lrp5 y metodos de uso | |
BR112017013568A2 (pt) | compostos bicíclicos fundidos para o tratamento de doenças | |
AR112602A1 (es) | ANTICUERPOS ANTI-TrkB | |
MX2019004690A (es) | Constructos de anticuerpos. | |
CL2018001139A1 (es) | Anticuerpos anti-htra1 y métodos de uso de los mismos. |